4 transcripts
FGEN
Earnings call transcript
NASDAQ
2024 Q2
6 Aug 24
, and radiographic progression-free survival using the prostate cancer working group criteria for tumor response assessment.
The completed Phase I trial
FGEN
Earnings call transcript
NASDAQ
2024 Q1
6 May 24
working group criteria for tumor response assessment. The completed Phase I trial includes a total of 56 pitot-static castration-resistant prostate cancer
FGEN
Earnings call transcript
NASDAQ
2023 Q4
26 Feb 24
with PET46. Patients will not be stratified at the start of the study, but the correlation between PET positivity and FG-3246 efficacy will be assessed
FGEN
Earnings call transcript
NASDAQ
2023 Q2
7 Aug 23
to 12 years of age. The primary endpoint is the North Star Ambulatory Assessment, a measure of ambulatory function, and we expect top line results
- Prev
- 1
- Next